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NICE DIAGNOSTIC ASSESSMENT REVIEWS – IS COST-EFFECTIVENESS ANALYSIS HELPFUL OR 
NECESSARY? 
 
Abstract  
Objective 
Diagnostic Assessment Reviews (DARs) are part of the work programme of the National 
Institute of Health and Care Excellence in England to evaluate emergent medical technologies 
and so ensure timely and consistent adoption within the NHS. New diagnostics have the 
potential to improve health outcomes and impact positively on NHS resource use. In this paper 
we reviewed published DARs to assess the quality of economic evidence available to NICE.   
 
Methods 
We reviewed 27 DARs that had been published by NICE as of 30 May 2017 by summarising and 
interpreting the evidence that was used to carry out cost-effectiveness analyses.  Common 
issues and challenges of the assessment process were illustrated.  
 
Findings 
DARs differed in the methods and assumptions used to construct economic models, and 
linkage of economic model and diagnostic findings. Even though some diagnostic technologies 
were estimated to be cost-effective, they were not always adopted for routine care in the NHS. 
The majority of DAR economic models relied heavily on assumptions and expert opinion, with 
considerable uncertainty about the cost-effectiveness of diagnostic testing. 
 
Conclusions 
DAR appraisals as commissioned by NICE typically feature varying evidence for diagnostic 
performance and limited evidence for resource implications and quality of life, often leading to 
recommendations for further research. Given the process opportunity cost, NICE might consider 
a two-stage topic selection process, with initial assessment specifying further research and 
proceeding to full assessment with adequate evidence. Such a process might help NICE signal to 
diagnostics companies the type of research evidence required. 
 
Keywords: Diagnosis, technology, assessment, cost-effectiveness, NICE 
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Introduction 
Diagnostic Assessment Reviews (DARs) are part of the National Institute for Health and Care 
Excellence (NICE) Diagnostics Assessment Programme (DAP) evaluating medical technologies 
and guiding the adoption of clinically worthwhile and cost-effective technologies by the 
National Health Service (NHS) in England in a timely and consistent manner. Diagnostic 
technologies include a diverse range of measurements and tests that are used to evaluate 
patients’ conditions.(1)  Examples include screening, diagnostic and monitoring tests to rule in 
or out specific diseases, to assess persistence or progression over time, to guide additional or 
sequential testing or the adjustment of treatment. (1-3)  
 
To establish the performance of a new test reliably it needs to be compared against an 
adequate reference standard in a representative population using adequate test accuracy 
methods. Additionally, innovative diagnostic technologies may improve health outcomes, but 
can come with a net cost to the health service. Such evidence is pivotal to an adequate 
assessment of the potential value of any new diagnostic technology.  The NICE DAR process 
has been described in detail elsewhere and the key steps involved in the DAR process are 
shown in Figure 1.(1) 
 
New, potentially promising, emergent diagnostic technologies are not yet part of routine care, 
with a poor clinical evidence base, present a common challenge.(1-3) Long-term data on 
health and resource impacts may be lacking and may need to be modelled using 
epidemiological and other data.(1)  For this reason, the NICE DAR process typically involves the 
de novo development of economic models to inform the cost-effectiveness analysis. However, 
while de novo modelling is challenging, it may be the only way to assess uncertainties and may 
help prioritise future research.   
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In this paper, we aim to review and assess the quality of economic evidence used in publicly 
reported DARs as part of NICE’s work programme. We highlight some of the common issues 
and challenges of the DAR assessment process.  We conclude with some recommendations 
about how the DAR process might evolve based on the findings from this review. 
 
Methods 
We searched the NICE website on 30 May 2017 for published guidance relating to the DAP and 
accessed the final Diagnostics Guidance (DG) report for each topic.(4)  Our assessment did not 
include supporting documentation such as External Assessment Group (EAG) reports, model or 
any addenda. Even though some of this information is publically available, some of the 
information is confidential and information on the website is redacted.  Therefore, to be 
consistent across the review process we only considered the final DG report using these as the 
basis for analysis, with the focus on cost-effectiveness evidence and recommendations.  
 
Data was extracted using a bespoke template in Microsoft Excel ® which included: disease 
area, the technologies and it comparators, stated benefits of the technology, prior cost-
effectiveness evidence, type of economic model developed by the EAG, technology costs, key 
outcomes, modelling methods, key assumptions and limitations, results, conclusions and 
recommendations by NICE. Data were extracted by one reviewer (HM) and checked by a 
second reviewer (JM); any disagreements in data extraction were resolved by discussion. 
Extracted data was synthesised narratively as appropriate.   
 
Quality assessment of diagnostic test accuracy studies can be assessed using the recently 
published Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic 
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Test Accuracy Studies: The PRISMA DTA Statement.(5) However, this assessment tool does not 
consider economic evidence per se.  Instead we have used Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) statement, the preferred tool to assess the quality of 
economic evaluation studies.(6)  
 
Findings 
As at 30 May 2017, NICE had published 27 DGs. Table 1 presents a summary overview of the 
main characteristics of each DG. DGs covered a wide range of diseases and disease areas 
including cancer, circulatory system, musculoskeletal system, liver disease, diarrhoea, allergies, 
type 1 diabetes, infections, and pre-eclampsia. The stated benefits of technologies considered 
by DGs included: improved imaging; quicker time to test reporting; reduced need for further 
testing, clinical consultation or hospital visits; and better information for decision-making and 
patient prognosis. 
 
In the following, we present the analysis of the DGs according to six themes: the nature of the 
comparator used; use of existing evidence of cost-effectiveness; reporting of methods; 
modelling assumptions; reporting of costs and outcomes; and findings and recommendations. 
 
Nature of the comparators  
In most cases, the new technology was compared with either the current technology or 
current standard clinical assessment, although the numbers of comparator interventions 
(range: 1-12) and comparator tests (range: 1-4) per appraisal varied. For example, DG11 
compared 12 new technologies for addressing irritable bowel disease or irritable bowel 
syndrome that measured faecal calprotectin levels alongside clinical practice and compared 
these with clinical practice alone (7), while DG21 assessed two technologies for managing 
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blood glucose levels in type 1 diabetics with four different comparators (Table 1).(8) Not all 
new technologies that were assessed sought to replace existing practice: in eight DGs, the new 
technologies were intended to augment standard clinical practice.(7, 9-15) Identifying a 
suitable comparator was sometimes problematic: DG7 reported that there was no direct 
comparator for the new technology (16), while for three DGs there were no direct test data 
available for some of the new tests.(8, 14, 17) Four DGs reported that the diagnostic 
technologies could not be compared with each other.(9, 10, 14, 18) 
 
Use of existing evidence and models of cost-effectiveness 
 Twenty one DGs were able to access  one or more existing studies with cost-effectiveness 
evidence (including one abstract (19) and one unpublished study provided by the 
manufacturer (20)). There was no relevant cost-effectiveness evidence available for two 
DGs(11, 21) while a further four DGs did not record this related information.(16, 22-24) A total 
of 18 DGs built de novo economic models(7, 9-17, 19-22, 24-28)  while ten DGs developed 
economic models based on existing previous models.(8, 18, 23, 29-34) For one DG, a 
conceptual model was built to explore diagnostic pathways due to the lack of clinical 
effectiveness data.(15)  
 
Reporting of methods used to develop economic models 
Methods used to construct economic models and link diagnostic findings, clinical and resource 
data varied between DGs and depended on available evidence. Relevant methods were not 
always explicitly reported (see Table 2). For fifteen DGs, the evidence for the economic model 
was derived from a clinical effectiveness review, supplemented by expert opinion. Nine DGs 
explicitly stated that a linked evidence approach was used for modelling. For example, 
intermediate outcomes such as test results obtained from the clinical effectiveness review 
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were linked to treatment outcomes and quality-adjusted life years (QALYs). (7, 10, 17, 21, 23, 
29) 
 
Modelling assumptions 
Reflecting the availability of clinical evidence, various assumptions were required within 
economic models, with the number of key assumptions being reported for more recent DGs.  
Key model limitations included: lack of clinical evidence or outcomes to estimate model 
parameters (17 DGs)(7, 9-12, 15-19, 22, 24, 26, 27, 30-32); lack of sensitivity and specificity for 
the new technologies (explicitly identified in 13 DGs)(7, 11, 13, 14, 16, 17, 20-22, 24, 26, 29, 
33); there was uncertainty about the assumption that the current practice/technology was an 
adequate reference standard (10 DGs)(7, 13, 18, 20, 23, 28-30, 33, 34); lack of evidence on 
quality of life and utilities (8 DGs)(11, 12, 15, 20, 21, 25, 30, 33); and, lack of clinical evidence to 
quantify patient benefits or preferences (2 DGs).(22, 29)   
 
Reporting of cost and outcomes 
Technology costs or per patient/sample test costs were reported in 19 DGs, with the most 
expensive being the new generation cardiac CT scanners (approximately £1 million each).(23)  
Eight DGs did not report technology costs or per patient/sample test costs.(11, 18, 20, 25, 27, 
31, 32, 34) The level of disaggregation with which costs were reported for technologies varied 
between DGs. These could include expected lifetime costs, maintenance, laboratory, 
disposables and other consumables costs, alongside staff, training and administration costs. 
Key clinical outcomes reported included mortality, morbidity, complications or adverse events, 
test performance and accuracy outcomes. Some DGs reported clinical outcomes used in the 
model within the cost-effectiveness analysis section, while in some instances clinical outcomes 
were not described specifically and had to be deduced from the clinical effectiveness review. 
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Seventeen DGs included some sort of disutility value or decrement to utility values in their 
model.(7-9, 11-14, 17-21, 25, 26, 30, 33, 34) All 27 DGs reported the final outcome for the 
economic models in terms of quality-adjusted life years.   
 
Findings and recommendations  
Figure 2 provides an illustration of the overall findings and recommendations issued by 
reviewed DGs. This highlights that just under half of the DGs (n=13) found the new 
technology/ies to be cost-effective (individually or as a class) while only one-third (n=9) 
recommended that the technologies be adopted in the NHS, although the nature of the 
recommendations was mixed. Five DGs found that the new technologies were not cost-
effective; of these, one DG recommended the reviewed technology for adoption for one 
specific group of patients only.(8) . Even though some technologies were estimated by 
modelling to be cost-effective, these were not always recommended by the Diagnostic 
Advisory Committee for routine adoption within the NHS, a finding that does not appear to 
have changed over time. For example, for DG19, even though the two assessed technologies 
were estimated to be cost-effective, the Committee stated that there was “currently 
insufficient evidence to recommend their routine adoption in the NHS”.(20)  In contrast, in 
DG21, even though the technology was not cost-effective it was recommended for adoption in 
the NHS: the Committee thought the technology would probably be cost-effective when 
changing some of the model assumptions.(8) 
 
Quality assessment 
Table 3 presents the number of items from each DG fulfilling each recommendation from the 
CHEERS checklist.  Among the 24 recommendations for reporting, eight items were not 
applicable.  All DGs reported the following five items: background and objectives, target 
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population and subgroups, setting and location, comparators, and choice of health outcomes.  
The other items where not consistently reported.  For example, only 10 DGs reported the 
study perspective and only 13 DGs reported the discount rate for the base-case analyses.  The 
discrepancies may have been due to the DGs not being reported in the traditional format of an 
economic evaluation.  
 
Discussion  
The NICE DAR programme aims to evaluate emerging diagnostic technologies, using clinical 
and cost-effective evidence, to guide adoption of new technologies within the NHS in England. 
We have reviewed 27 completed diagnostic guidance reports.   
 
Superficially, all 27 DARs to date have reported cost/QALY findings with which to inform NICE 
decision-making, consistent with stated requirements.  However, there is considerable 
heterogeneity in methods, availability and use of evidence, as well as instances of the NICE 
committee not accepting the (median) findings of cost-effectiveness models mainly due to the 
insufficient clinical evidence for new technologies.  
 
A limitation of our review was that it was limited to published Diagnostic Guidance (DG), and 
more information and detail might have been obtained from the EAG reports. We did not 
include any other information available on the NICE website as this varied between appraisals 
– mainly in terms of confidential information redacted and we wanted to take a consistent 
approach in our assessment. However, some common challenges are apparent, modelling a 
pathway of care, evidenced where possible but substantially reliant on expert opinion and 
assumptions, with extensive sensitivity analysis needed to explore the robustness of findings.  
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Given the extent of modelling uncertainties, their comprehensive characterisation would tend 
to lead to inconclusive findings. 
 
The purpose of our review was an assessment of the fitness for purpose of the NICE Diagnostic 
Assessment Reviews, initiated by our own experience completing a review.(28)  This did not 
extend formally to look at experiences in our countries or whether other contexts face similar 
issues.  However, the diagnostic evidence and extant cost-effectiveness considered within 
DARs was international and not constrained to the NHS setting.  Thus the challenges 
experienced by NICE are likely to be found more globally, although different health care 
systems put different emphasis on the importance of the clinical evidence economic 
evaluation.(35)  
 
Diagnostic tests may originate from the largest medical device companies to small venture 
capital start-ups and clinician-driven ventures, with consequent variation in capacity to fund 
adequate research.  It is not clear that the current appraisal process signals to diagnostics 
companies the type and depth of research required to inform NICE recommendations.  
Although context specific it may be helpful for developers of new tests to be more aware of 
the generic needs of cost-effectiveness models.  As a first step, diagnostic accuracy studies 
should usefully describe the performance and potential of new and existing tests, where an 
independent reference standard is available.  However, these studies often don’t capture the 
comparative costs and outcomes that follow.  An adequate test-treat trial, with patients from 
the relevant population randomised to new and current diagnostic tests, and capturing costs 
and outcomes (ideally generic quality-of-life) may provide the best evidence.(1)  This approach 
is particularly valuable when identifying an adequate reference standard is problematic.  
Accurate costing information for new tests should include the full set-up, running and 
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maintenance costs, including staff equipment and site costs and explore plausible volume-of-
use and disease prevalence assumptions.(36-38) 
 
Although the mechanism for topic selection used by NICE has been described, it is unclear how 
it is informed.  On the basis of past selection assessed in this review, adequate maturation of 
evidence does appear influential.  While adequate evidence may not guarantee a definitive 
answer, an immature evidence base is almost certain to yield uncertain findings.  Possibly this 
is a legitimate goal for NICE and ‘don’t know yet’ is a helpful policy outcome.  A further 
complexity for topic selection is the expectation that new diagnostic technologies tend to 
evolve, create challenges for evidence requirements, the timing of appraisal and subsequent 
adoption decisions.  In this respect, NICE may be ‘between a rock and a hard place’ with no 
optimal solution.  
 
The inception of the DG pathway was intended as a route for manufacturers to gain rapid and 
consistent adoption of new diagnostic tests within the NHS.  Since the flow of work through 
the DAR work stream has diminished, there may be a perception from manufacturers that the 
process isn’t delivering the hoped-for access.  From the academic perspective, the substantial 
work to construct a cost/QALY model may not feel appropriate or efficient given that findings 
may be dominated by the typical clinical uncertainties we have identified.  There are 
considerable pressures on NICE’s capacity to service its expanding programme of evaluation. 
Consequently, full economic analysis might be better reserved for topics where the weight of 
clinical evidence passes some threshold.  A two stage process might involve an initial 
assessment of promising technologies, identifying a research pathway where necessary, with 
final assessment where adequate evidence is available to inform NICE recommendations.  This 
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assessment process would assess each of the three domains of performance, cost and 
outcome. 
 
Conclusion 
NICE recommendations for adoption of new diagnostic are cautious, of 27 assessments, there 
were 10 cases of adoption and 9 cases of limited adoption of new diagnostic technologies.  The 
primary issue, given the opportunity cost of the process, is whether these assessments are 
optimally selected or timed.  NICE might consider a two-stage topic selection process, with initial 
assessment with adequate evidence.  Such a process might help NICE signal to diagnostic 
companies the type of research evidence required. 
 
 
Funding: This paper derives in part from a review commissioned by the NIHR HTA Programme 
as project number 15/17/03. The views expressed in this report are those of the authors and 
not necessarily those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of 
Health. Any errors are the responsibility of the authors. 
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Table 1: Main characteristics of 27 Diagnostic Guidances published by NICE by 30 May 2017 
DG*  Disease area 
Intervention \ Comparator  
Intervention 
benefits 
Cost-
effectiveness 
evidence? 
Model type Costs Outcomes 
DG1(1) Musculoskeletal system: spinal deformity. 
EOS 2D/3D X-ray imaging system.  Comparator: 
conventional (computed or digital) 
radiography.  
Produces 2D 
images similar to 
conventional 
radiology, as well as 
3D images. 
Not 
mentioned 
De novo 
economic 
model 
EOS system costs £400k plus 
maintenance cost of £32k p.a. 
Conventional radiography 
costs £95k (£105-£230k), plus 
maintenance cost of £10k 
(£18k) p.a. 
The primary outcome 
measure was cancer 
reduction. 
Quality-adjusted life 
years (QALYs) were used 
in the economic model. 
DG3(2) Circulatory system: coronary artery disease. 
New generation cardiac computed tomography 
(CT) scanners (Aquilion ONE, Brilliance iCT, 
Discovery CT750 HD and Somatom Definition 
Flash). Comparator: invasive coronary 
angiography. 
New scanners have 
advanced technical 
features including 
better resolution 
and shorter 
acquisition times. 
Not 
mentioned 
Diagnostic 
model based on 
linking 5 
existing models 
(decision trees 
and Markov 
models) 
Cost of each new CT scanner 
was assumed to be £1 million 
(ranges from £900k to £1.1m). 
Complication rate for 
angiography, reduction in 
cancer incidence as a 
result of reducing 
radiation dose, morbidity 
and mortality. 
QALYs were used in the 
economic model. 
DG4(3) Cervical cancer. 
DySIS and Niris imaging system. Comparator: 
conventional colposcopy. 
New adjunct 
devices – with 
similar benefits.  
No studies 
were 
identified 
Model created 
with two sub 
models 
(decision tree 
and a Markov 
model) 
DySiS costs ranges from £18-
£22k including colposcope. 
Niris costs approx. £31k in 
addition to the colposcope 
costs. Conventional 
colposcope costs £10k plus 
£1k p.a maintenance costs. 
Diagnostic test accuracy 
outcomes, adverse 
events, patient 
experience, morbidity 
and mortality.  
QALYs were used in the 
economic model. 
DG5(4) Liver disease imaging for: 1) Cirrhosis 
surveillance; 2) colorectal cancer; 3) liver lesion 
unrelated to their clinical condition. 
SonoVue contrast agent used for enhanced 
ultrasound imaging. Comparator: contrast-
enhanced CT and/or magnetic resonance 
imaging (MRI). 
SonoVue improves 
display of blood 
vessels in liver 
lesions during 
sonography and 
allows better 
characterisations of 
lesions. 
Four studies 
were 
identified 
Three de novo 
models created 
for three 
patient groups 
using three 
existing models 
The costs of contrast agent, 
including cannulation, were 
£48.70.  The total additional 
cost for doing contrast-
enhanced ultrasound was 
estimated to be £65. 
Morbidity, mortality and 
impact of adverse events 
associated with 
treatment (i.e. 
chemotherapy). 
QALYs were used in the 
economic model. 
DG6(5) Patients who are at higher risk of unintended 
awareness during general anaesthesia. 
Electroencephalography (EEG)-based depth 
monitors: Bispectral Index (BIS), E-Entropy and 
Narcotrend-Compact M used with standard 
clinical monitoring. Comparator: standard 
clinical monitoring. 
EEG-based 
monitors indicate 
the probability of 
consciousness with 
explicit recall in 
patients receiving 
general 
anaesthetics. 
One study was 
identified 
Three de novo 
decision models 
for each of the 
monitors 
Monitor costs varied from 
£4,867 (BIS) to £10,825 
(Narcotrend-Compact M).  
 
Post-operative nausea 
and vomiting, post-
traumatic stress disorder 
and post-operative 
cognitive dysfunction. 
QALYs were used in the 
economic model. 
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DG*  Disease area 
Intervention \ Comparator  
Intervention 
benefits 
Cost-
effectiveness 
evidence? 
Model type Costs Outcomes 
DG7(6) Chronic diarrhoea associated with: irritable 
bowel syndrome (IBS); and Crohn's disease 
without ileal resection. 
SeHCAT (tauroselcholic [selenium] acid) test. 
Comparator: no common direct comparator, 
instead a protocol of tests and clinical 
observations was used. 
SeHCAT helps 
diagnose bile acid 
malabsorption and 
may reduce the 
need for further 
diagnostic tests and 
clinician visits. 
Not 
mentioned  
(24 studies 
identified to 
estimate 
model 
parameter 
values) 
De novo 
decision tree 
and Markov 
model  
A SeHCAT capsule costs £195 
and administering the SeHCAT 
test costs were £186. 
Life expectancy, 
mortality, and utility 
values obtained from the 
literature. 
QALYs were used in the 
economic model. 
DG8(7) Early invasive breast cancer.  
Intraoperative molecular tests: RD-100i OSNA 
system or the Metasin test. Comparator: post-
operative hispathology (a second operation is 
dependent on waiting for test results). 
These tests are 
designed to be 
available during 
surgery to 
determine whether 
other lymph nodes 
should be removed 
at the same time. 
Two studies 
were 
identified 
De novo 
decision tree for 
diagnostic 
strategies and a 
discrete event 
simulation 
model for 
management 
pathways 
(based on an 
existing model) 
Unit cost of the RD-100i OSNA 
system was £350 and the unit 
cost of histopathology was 
£472. 
Test performance i.e. 
diagnostic accuracy, 
anxiety waiting for test 
results, number of repeat 
operations and morbidity 
and mortality. 
QALYs were used in the 
economic model. 
DG9(8) Locally advanced or metastatic non-small-cell 
lung cancer. 
Ten epidermal growth factor receptor tyrosine 
kinase (EGFR-TK) mutation tests: 3 are CE-
marked; 5 are laboratory-developed; and 2 are 
test strategies.  Comparator: Sanger or direct 
sequencing (a screening method of mutation 
detection). 
Patients with 
positive tumours 
gain more benefit 
from treatment 
with EGFR-TK tests 
than standard 
chemotherapy. 
Not 
mentioned 
De novo 
decision and  
Markov model 
(based on an 
existing model) 
Test costs were based on the 
NHS laboratory prices ranged 
from £130 (Sanger 
sequencing or cobas EGFR 
Mutation Test) to £187.50 
(Pyrosequencing). 
Progression-free and 
overall survival, technical 
performance, and test 
accuracy. 
QALYs were used in the 
economic model. 
DG10(9) Adjuvant chemotherapy decisions for people 
with early breast cancer. 
Two gene expression profiling tests: 
MammaPrint and Oncotype DX; and two 
immunohistochemistry tests: IHC4 and 
Mammostrat, all used in conjunction with 
current practice. Comparator: standard 
practice.  
Tests measure 
multiple markers 
within the tumour 
and may indicate 
how the tumour is 
likely to develop. 
Four studies 
were 
identified 
De novo state 
transition 
economic 
model 
Tests costs were: 
MammaPrint was £2,675, 
Oncotype DX was £2,580, 
IHC4 was £150, and 
Mammostrat was £1,135. 
Test accuracy, predict the 
risk of an outcome 
(prognostic ability), 
clinical utility, morbidity, 
mortality and adverse 
events. 
QALYs were used in the 
economic model. 
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DG*  Disease area 
Intervention \ Comparator  
Intervention 
benefits 
Cost-
effectiveness 
evidence? 
Model type Costs Outcomes 
DG11(10) Inflammatory bowel disease (IBD) or irritable 
bowel syndrome (IBS). 
12 tests that measure calprotectin level in 
stool samples alongside clinical practice: 7 fully 
quantitative laboratory-based tests, 3 fully 
quantitative rapid tests and 2 semi-
quantitative point-of-care tests (POCTs). 
Comparator: standard clinical practice. 
Faecal calprotectin 
test results can be 
interpreted easily 
using cut-off values 
and can influence 
the diagnostic 
accuracy of the 
tests. 
Seven studies 
were 
identified 
De                   
novo economic 
model 
Per patient costs of a fully 
quantitative laboratory-based 
tests was £22.79 and a POCT 
was £24.03. Colonoscopy 
costs £741.68 per person. 
Morbidity and mortality. 
QALYs were used in the 
economic model. 
DG12(11) Asthma in adults and children. 
Fractional exhaled nitric oxide (FeNO) testing 
using three devices: NIOX MINO, NIOX VERO 
and NObreath. Comparator: current standard 
tests. 
FeNO testing is a 
non-invasive 
marker of asthma 
airway 
inflammation.  
Two studies 
were 
identified 
2 de novo 
models: 
decision tree 
(diagnostic) and 
Markov model 
(management) 
Marginal per-test costs for all 
3 devices were based on 
information from the 
manufacturers (not reported 
in the DG). 
Test accuracy and quality 
of life. 
QALYs were used in the 
economic model. 
DG13(12) Detect, manage and monitor haemostasis in 
patients having cardiac surgery and trauma 
surgery. 
Three viscoelastometric POCT devices (ROTEM, 
TEG and Sonoclot systems). Comparator:  
combination of clinical judgement and 
standard laboratory tests. 
Testing helps guide 
clinicians in 
selecting 
appropriate 
treatments to stop 
bleeding. 
Five studies 
were 
identified  
Decision model 
based on a 
previous model 
Costs for the 3 devices 
included device costs, the 
costs of extra items and after-
care and training costs (not 
reported in the DG). 
Adverse events, 
complications and red 
blood cell transfusion. 
QALYs were used in the 
economic model. 
DG14(13) People with atrial fibrillation or heart valve 
disease who are at risk of thrombosis. 
Two POCT self-monitoring coagulators: 
CoaguChek XS and INRatio2 PT/INR. 
Comparator: international normalised ratio 
(INR) testing using laboratory analysers or 
POCT. 
Coagulometers may 
reduce the 
frequency of 
hospital visits or 
clinics for patient. 
12 studies 
were 
identified 
De novo Markov 
model based on 
a review of 
previous models 
Costs for the different 
monitoring strategies were 
based on the manufacturers' 
and suppliers' prices (not 
reported in the DG). 
 
Frequency of bleeds or 
blood clots, morbidity 
and adverse events. 
QALYs were used in the 
economic model. 
DG15(14) Diagnosis of acute myocardial infarction.  
Three high-sensitivity assays: Elecsys Troponin 
T; ARCHITECT STAT Troponin-I; and AccuTnI+3 
troponin I. Comparator: standard testing over 
10–12 hours. 
New troponin 
assays have a 
quicker turn-
around time (in 
minutes rather 
than hours). 
Five studies 
were 
identified 
De novo 
decision and  
Markov model 
(based on an 
existing model) 
 
Average cost of a troponin 
test (high-sensitivity or 
standard) to the NHS is £20. 
Diagnostic and 
prognostic accuracy. 
QALYs were used in the 
economic model. 
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DG*  Disease area 
Intervention \ Comparator  
Intervention 
benefits 
Cost-
effectiveness 
evidence? 
Model type Costs Outcomes 
DG16(15) Continuous infusion 5-fluorouracil (5-FU) 
chemotherapy to treat many cancers.  
My5-FU assay to measure the levels of 5-FU 
chemotherapy in plasma samples. Comparator: 
body surface area dosing.  
 
My5-FU assay aims 
to achieve an 
optimal plasma 
level of the drug. 
One abstract 
was identified 
De novo 
economic 
model. 
A cost per completed My5-FU 
assay of £61.03 (which 
included laboratory costs and 
community health visitor 
costs). 
Diagnostic accuracy, dose 
adjustments, 
progression-free and 
overall survival, 
treatment response 
rates, toxicity and side 
effects. 
QALYs were used in the 
economic model. 
DG17(16) People with suspected prostate cancer.  
Two in vitro diagnostic tests: PROGENSA PCA3 
assay and Prostate Health Index (PHI) 
alongside clinical assessment.  Comparator: 
clinical assessment or clinical assessment plus 
MRI. 
Tests detect 
specific biomarkers 
and which can 
suggest the 
presence of cancer.  
No studies 
were 
identified 
De novo 
economic 
model 
Costs for the different 
diagnostic strategies were 
informed by literature, 
existing guidance and 
companies’ prices (not 
reported in the DG). 
 
Clinical and analytical 
validity, and the number 
of biopsies needed. 
QALYs were used in the 
economic model. 
DG18(17) Adults and children with suspected sepsis or 
suspected bacterial infections. 
Five procalcitonin tests: ADVIA Centaur 
BRAHMS PCT assay, BRAHMS PCT Sensitive 
Kryptor assay, Elecsys BRAHMS PCT assay, 
LIAISON BRAHMS PCT assay and VIDAS 
BRAHMS PCT assay in addition to standard 
clinical practice. Comparator: standard clinical 
practice without procalcitonin testing. 
Procalcitonin 
testing can help 
clinicians to guide 
antibiotic 
treatment. 
Two studies 
were included 
Two de novo 
decision tree 
models 
Average unit price for the 
procalcitonin test was £13.79, 
based on the list prices of the 
tests. 
Antibiotic related 
adverse events, 
mortality, and resource 
use such as intensive 
care length of stay. 
QALYs were used in the 
economic model. 
DG19(18) Diagnosis of skin cancer. 
Two imaging systems: VivaScope 1500 and 
3000.  Comparator: dermoscopy and clinical 
judgement. 
New technologies 
that can image 
tissue at a cellular 
level in real time. 
No studies 
were 
identified, 
unpublished 
study was 
provided by 
manufacturer. 
De novo 
decision tree 
and Markov 
model 
Cost of diagnostic assessment 
with VivaScope after 
dermoscopy (not reported in 
the DG). 
 
Diagnostic accuracy. 
QALYs were used in the 
economic model. 
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DG*  Disease area 
Intervention \ Comparator  
Intervention 
benefits 
Cost-
effectiveness 
evidence? 
Model type Costs Outcomes 
DG20(19) Bloodstream infections such as sepsis. 
Three molecular tests:  LightCycler SeptiFast 
Test MGRADE, SepsiTest and IRIDICA BAC BSI 
assay used with clinical assessment. 
Comparator: standard care - blood culture 
alone or blood culture with mass 
spectrometry. 
Tests can rapidly 
detect and identify 
bacterial and fungal 
DNA that may be in 
the bloodstream. 
Four studies 
were included 
Conceptual 
decision tree 
model 
LightCycler SeptiFast Test 
MGRADE £153.67 to £205.54; 
SepsiTest £108.30 to £149.53; 
IRIDICA BAC BSI £197.35 to 
£314.61; MALDI-TOF MS 
£6.94 to £232.39 
Diagnostic accuracy, 
mortality, duration of 
stay in intensive care unit 
or hospital, test failure 
rates and antimicrobial 
treatment.  
QALYs were used in the 
economic model. 
DG21(20) Managing blood glucose levels in people with 
type 1 diabetes. 
Two tests: MiniMed Paradigm Veo system and 
the Vibe and G4 PLATINUM CGM System. Four 
comparators: capillary blood testing or 
continuous glucose monitoring with 
continuous subcutaneous insulin infusion or 
with multiple daily insulin injections. 
These systems may 
improve glucose 
control and reduce 
the number of 
diabetes-related 
complications and 
improve quality of 
life. 
Two studies 
were 
identified 
Based on IMS 
CORE Diabetes 
Model (a 
simulation 
model)  
Costs of the MiniMed 
Paradigm Veo system and the 
Vibe and G4 PLATINUM CGM 
system were £2,962 and 
£3,195 respectively. 
Reduction in HbA1c from 
baseline and number of 
severe hypoglycaemic 
events. 
QALYs were used in the 
economic model. 
DG22(21) Crohn’s disease:  people whose disease loses 
response to or responds to tumour necrosis 
factor (TNF)-alpha inhibitors.  
Three index tests:  LISA-TRACKER, IDKmonitor, 
and Promonitor Enzyme-Linked 
Immunosorbent Assay (ELISA) kits. 
Comparator: clinical judgement. 
New index tests 
shows promise for 
therapeutic 
monitoring i.e. 
measuring levels of 
TNF-alpha 
inhibitors. 
Four studies 
were 
identified 
Two de novo 
Markov models 
Per patient costs: 
LISA-TRACKER - £20.24, 
IDKmonitor drug level - 
£21.38 and IDKmonitor 
antidrug antibodies - £17.22, 
and Promonitor - £20.00. 
Diagnostic accuracy and 
test performance. 
QALYs were used in the 
economic model. 
DG23(22) Help diagnose suspected pre-eclampsia in 
pregnancy. 
Four placental growth factor (PIGF) index 
based tests: Triage PlGF test; Elecsys 
immunoassay sFlt-1/PlGF ratio; DELFIA Xpress 
PlGF 1-2-3; and BRAHMS sFlt-1 
Kryptor/BRAHMS PlGF plus Kryptor PE ratio in 
addition to standard clinical assessment. 
Comparator: standard clinical assessment 
alone. 
PIGF-based tests in 
addition to 
standard care could 
result in a faster 
and more accurate 
diagnosis of pre-
eclampsia. 
Four studies 
were 
identified 
De novo 
decision tree 
model 
The list price for a single 
Triage PlGF test is £40 and for 
a single Elecsys immunoassay 
sFlt-1/PlGF ratio is £57.23.  
 
Diagnostic test accuracy 
and prevalence of pre-
eclampsia. 
QALYs were used in the 
model. 
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Intervention \ Comparator  
Intervention 
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Cost-
effectiveness 
evidence? 
Model type Costs Outcomes 
DG24(23) Allergies including food or skin. 
Multiplex allergen testing: ImmunoCAP 
ISAC 112 or Microtest used with standard 
clinical assessment. Comparator: standard 
clinical assessment alone. 
 
Multiplex allergen 
testing allows 
clinicians to test for 
multiple allergens 
at the same time.  
Nine studies  
were 
identified 
Conceptual 
decision tree 
and Markov 
model  
Test costs include capital, 
service, maintenance costs, 
and personnel costs. 
Minimum and maximum 
costs: ImmunoCAP ISAC 112 – 
£154.41 to £284.60 & 
Microtest - £140.37 to 
£173.33 
Diagnostic accuracy,  
Long-term outcomes in 
the model could be 
QALYs. 
DG25(24) Pregnant women who are rhesus-D (D) 
negative and not sensitised to D antigen. 
High-throughput non-invasive prenatal testing 
(NIPT): Comparator: Cord blood typing. 
NIPT can help avoid 
unnecessary 
treatment with 
anti-D 
immunoglobulin. 
Seven studies 
were 
identified 
 
De novo 
decision tree 
model 
Costs include consumables, 
staffing, equipment, indirect 
and overhead costs (not 
reported in the DG).  
Cord blood typing plus 
phlebotomy is £7.50. 
Diagnostic accuracy, test 
performance and 
mortality. 
QALYs were used in the 
model. 
DG26(25) Gastroenteritis: diarrhoea and/or vomiting.  
Three integrated multiplex polymerase chain 
reaction tests: xTAG Gastrointestinal Pathogen 
Panel (GPP), FilmArray GI Panel and the Faecal 
Pathogens B assay. Comparator: syndromic 
algorithm for routine testing in sporadic cases 
(conventional testing). 
New tests can 
produce results in a 
much shorter 
timeframe. 
One study was 
identified 
 
Five de novo 
decision tree 
models 
 
Per sample test costs: 
Conventional test - £66.18; 
XTAG GPP - £37.10; and 
FilmArray GI panel – £93.53. 
Diagnostic accuracy and 
test turnaround times.  
QALYs were used in the 
model. 
DG27(26) Colorectal cancer due to Lynch syndrome. 
Tumour testing strategies: microsatellite 
instability or immunohistochemistry both with 
and without further testing and 
comprehensive mismatch repair. Comparator: 
No testing. 
Improved patient 
outcomes through 
earlier diagnosis 
and treatment. 
Nine studies 
were 
identified 
 
De novo 
decision and  
simulation 
model (based 
on an existing 
model) 
 
Costs included tumour 
testing, genetic tests and 
counselling (not reported in 
the DG). 
Outcomes relating to 
surveillance, treatment 
and test accuracy.   
QALYs were used in the 
model. 
DG28(27) Colorectal polys and colorectal cancer. 
Three virtual chromoendoscopy tests: Narrow 
Band Imaging (NBI), Flexible spectral imaging 
colour enhancement (FICE), i-scan. 
Comparator: Histopathology. 
Real-time 
interactions, 
quicker results and 
management 
decisions. 
Two studies 
were 
identified 
De novo 
decision and  
state transition 
model (based 
on an existing 
model) 
 
Tests costs not reported in 
the DG. Costs of colonoscopy 
with and without 
polypectomy were £518 and 
£600, respectively.  Other 
costs included: surgery, 
admissions, adverse events 
and training. 
Test accuracy and 
adverse events. 
QALYs were used in the 
model. 
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*DG2 is not available on the website. DG2 was a review of Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia and guidance was first 
issued in 2011 and the index tests were not recommended for use in the NHS.  The diagnostics guidance was later withdrawn as the companies confirmed that the 
two index tests were no longer available. 
Table 2: Main results and conclusions, methods used, assumptions and key limitations associated with the different Diagnostic Guidance’s 
DG Key results Conclusion Methods used 
Main assumptions 
Limitations 
DG1(1) £148k to over £15m per QALY 
gained depending on indicated 
use (a single machine for an 
entire country, with usage to 
only the studied conditions and 
no other use for the machine). 
EOS an important emerging 
technology, however, not a cost-
effective use of NHS resources. 
Further research is needed to 
quantify the health benefits 
associated with EOS imaging for 
different conditions. 
Modelling explored the most prevalent forms of cancer. 
Modelling used to link dose reduction to reduced 
cancer occurrence.  
Base-case analysis used computed radiography as its 
comparator. Different throughputs for machine usage. 
 
No clinical evidence to quantify 
patient benefits from the EOS 
systems. 
No studies followed patient to 
final outcomes.  
No evidence for sensitivity and 
specificity for the EOS system. 
DG3(2) New generation CT scanners 
were cost-effective compared 
with invasive coronary 
angiography. 
New CT scanners are 
recommended as a first line option 
for people with suspected 
coronary artery disease in whom 
imaging with earlier CT scanners is 
difficult. 
Linked evidence approach linking diagnostic accuracy of 
tests to treatment outcomes and QALYs.  
Invasive coronary angiography was the ‘gold standard’. 
Even though test accuracy data 
existed is was not stratified by 
difficult to image subsets. 
DG4(3) In all scenarios DySIS colposcopy 
dominated standard colposcopy. 
DySIS is a cost-effective option, 
compared with standard 
colposcopy.  Insufficient evidence 
to determine whether the Niris 
Imaging System is cost-effective. 
Linked evidence approach linking results of the test(s) 
to treatment outcomes and QALY gains. 
The Markov model was based on an existing model. 
Further analyses included: a higher QALY decrement 
and cost associated with excision treatment biopsy. 
Sensitivity and specificity 
estimates not reliable for the Niris 
system, therefore a full economic 
analysis was not possible. 
DG5(4) Model 1 and 3: SonoVue 
dominated the comparators. 
Model 2: SonoVue and contrast-
enhanced CT were cost-effective 
technologies. 
Contrast enhanced ultrasound 
with SonoVue is recommended for 
detecting focal liver lesions in 
adults for whom an unenhanced 
ultrasound scan is inconclusive. 
Linked evidence approach linking results of the test(s) 
to care pathway to estimate clinical outcomes and 
QALY gains. 
Model 1: sensitivity for identifying large hepatocellular 
carcinomas was 100%. SonoVue performed in the same 
appointment as the unenhanced ultrasound scan. 
Studies in the review were poor 
quality i.e. lack of information on 
disease progression and 
management, equipment choice, 
costs, health outcomes, test 
accuracy, and short follow-up. 
No data on patient preferences. 
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DG Key results Conclusion Methods used 
Main assumptions 
Limitations 
DG6(5) Patients at high risk of adverse 
outcomes from anaesthesia, all 3 
monitors were cost-effective 
compared to standard care. 
Patients at general risk of 
adverse events from 
anaesthesia, the BIS and E-
Entropy monitors were cost-
effective compared to standard 
care, however, Narcotrend-
Compact M dominated standard 
care. 
All three monitors were 
recommended as options during 
any type of general anaesthesia in 
patients considered at higher risk 
of adverse outcomes. 
Three separate models were developed: 1 for each 
monitor all with the same model structure but with 
model parameters varying.  
Effect estimates derived for BIS were applied to the 
other two monitors due to the lack of data. 
No direct comparisons of the 3 
monitors was performed. 
No short-term adverse outcomes 
on quality of life was included in 
the model. 
No robust evidence for the clinical 
benefits for E-Entropy or 
Narcotrend-Compact M monitors. 
 
DG7(6) The results showed that there 
was considerable uncertainty 
about the cost-effectiveness of 
SeHCAT testing for both patient 
groups. 
Insufficient evidence to determine 
whether SeHCAT is a cost-effective 
option for diagnosing bile acid 
malabsorption in the two patient 
groups and further research is 
needed. 
Model populated with information from systematic 
review. A survey eliciting expert opinion was done 
when no evidence was found in the literature.   
No direct comparator for this test, a protocol of tests 
and clinical observations was used as the comparator. 
No information to estimate 
transition probabilities in the 
Markov models other than for all-
cause mortality. 
There was no clinical validity and 
test accuracy results for SeHCAT. 
DG8(7) The long-term model found that 
the whole-node OSNA analysis 
was cheaper and less effective 
than hispathology.  
 
RD-100i OSNA system is 
recommended as an option during 
breast surgery in people with early 
invasive breast cancer. The 
Metasin test is not recommended 
for people with early invasive 
breast cancer. 
The discrete event simulation model for the long-term 
management was based on a previous published 
model. 
QALY decrements were estimated for waiting for 
hispathology results and for having a second separate 
operation. Hispathology was assumed to be the gold 
standard (100% sensitivity and specificity). 
Heterogeneity in hispathology 
definitions and how it is 
performed in the NHS. 
Only single-centre observational 
studies were found in the 
literature review.  
Only unpublished evidence was 
available for the Metasin test. 
DG9(8) The results showed that there 
was considerable uncertainty 
about the cost-effectiveness of 
the 10 different tests where 
some results indicated that tests 
where both less effective and 
less costly. 
 
Five tests are recommended for 
detecting EGFR-TK mutation.   
For the other five tests not enough 
evidence to allow any 
recommendations to be made on 
their use. 
Different approaches:  
1) comparative effectiveness (progression-free survival 
and overall survival); 2) linked evidence (test accuracy 
data) 3) equal prognostic value analysis (assuming no 
data on 1) and 2)). Test strategies only differed with 
respect to costs. 
The turnaround time was not included in the model. 
Greater number of assumptions needed due to lack of 
data on cost and overall survival. 
Lack of gold standard for assessing 
test accuracy, difficulties relating 
to the different mutation coverage 
of the various tests, and the 
uncertainty about the clinical 
significance of some mutations. 
Lack of data for 2 tests so not 
included in the cost-effectiveness 
analysis (next-generation 
sequencing and the therascreen 
EGFR Pyro) 
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DG Key results Conclusion Methods used 
Main assumptions 
Limitations 
DG10(9) Oncotype DX was cost-effective 
compared to current practice. 
ICH4 was predicted to be 
dominant compared with 
current practice. 
Oncotype DX is recommended as 
an option for chemotherapy 
decisions for people with early 
breast cancer. MammaPrint, IHC4 
and Mammostrat are only 
recommended for use in research 
in people with early breast cancer. 
Cancer registry data on chemotherapy was used for 
standard practice. Linked evidence approach linking 
test results to treatment outcomes and QALY gains. 
Assumptions included: test reproducibility and the use 
of risk groups as opposed to a continuous risk score. 
No evidence of IHC4 to predict 
benefit from chemotherapy. 
Exploratory analyses for 
Mammostrat and MammaPrint as 
evidence base and UK data were 
limited. 
Oncotype DX and IHC4; 
Mammostrat; MammaPrint 
cannot be compared directly 
compared as data from different 
studies with different patient 
characteristics and methodologies. 
DG11(10) Primary care adults comparing 
IBD with IBS: faecal calprotectin 
strategies dominated current 
practice. 
Secondary care paediatrics 
comparing IBD with non-IBD: 
prior testing using fully 
quantitative tests dominated 
current practice. 
Faecal calprotectin is a cost-
effective use of NHS resources. 
Linked evidence approach linking faecal calprotectin 
test results to treatment outcomes and QALY gains. 
Reference standard was histology after endoscopy. 
Assumed 100% specificity for patients undergoing 
colonoscopy. 
Limited data on the comparative 
effectiveness of the different 
tests. 
Model did not incorporate how 
people with indeterminate results 
would be followed up before 
receiving a colonoscopy. 
Minor adverse events costs were 
excluded. 
DG12(11) FeNO testing in conjunction with 
existing tests is more cost-
effective than when using 
existing tests alone. 
 
FeNO testing is recommended as 
an option to help diagnose asthma 
in adults and children.  
Evidence for the model came from systematic review 
for clinical effectiveness. 
Quality of life estimated using an EQ-5D regression 
model and disutilities associated with asthma were 
applied.  All three tests were assumed to be broadly 
equivalent. 
Lack of evidence on time needed 
to resolve incorrect diagnoses – 
values elicited from clinical 
specialists. 
Lack of gold standard for asthma 
diagnosis. 
Absence of a meta-analysis 
indicated uncertainty around the 
accuracy of the devices. 
DG13(12) For both the cardiac and the 
trauma models, all devices 
dominated standard laboratory 
tests. 
ROTEM and TEG systems are 
recommended during and after 
cardiac surgery. Sonoclot system 
only recommended for use in 
research. 
For both the cardiac and trauma models, the models 
adopted a similar structure to a previous model. 
No difference in the clinical effectiveness of studies 
assessing ROTEM and TEG, therefore the systems were 
assumed to be equivalent. 
Lack of evidence to model 
management of postpartum 
haemorrhage. 
Trauma model structure was 
subject to uncertainty as it was 
driven by a decrease in transfusion 
rather than outcomes and 
mortality. 
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DG Key results Conclusion Methods used 
Main assumptions 
Limitations 
DG14(13) The self-monitoring strategies 
compared favourably with 
standard care. The INRatio2 
PT/INR monitor dominated 
standard monitoring and the 
incremental cost-effectiveness 
ratio (ICER) for the CoaguChek XS 
system was £319 per QALY 
gained compared with standard 
monitoring.  
CoaguChek XS system and 
InRatio2 PT/INR monitor are 
recommended for self-monitoring 
coagulation status in adults and 
children. 
Model populated using data from the clinical 
effectiveness review, supplemented with expert 
opinion. 
Assumptions included: relative treatment effects were 
estimated and applied separately for self-testing and 
self-management, and 67% of standard monitoring was 
done by nurses. 
There was greater uncertainty of 
clinical benefit for the InRatio2 
PT/INR monitor, but it was 
appropriate to extrapolate from 
CoaguChek XS system, as they had 
similar performance in precision 
and accuracy with regard to time 
in therapeutic range 
measurement. 
DG15(14) The ICERs for the high-sensitivity 
test strategies ranged from 
£24,019 to £90,725 saved per 
QALY lost compared with 
standard testing.  Elecsys 
Troponin T assay and ARCHITECT 
STAT Troponin-I assay were cost-
effective, but the cost-
effectiveness evidence for the 
AccuTnI+3 assay was not robust. 
The Elecsys Troponin T assay and 
ARCHITECT STAT Troponin-I assay 
are recommended as options for 
the early rule out of myocardial 
infarction.  AccuTnI+3 assay only 
recommended in use for clinical 
research. 
Evidence including test accuracy estimates for the 
model came from the clinical effectiveness review. 
Comparator has perfect diagnostic accuracy.  Life 
expectancy, quality of life and costs for people with 
false-positive results and true negative results is equal. 
No additional benefit of starting treatment early. A 
total delay of 3 hours is assumed. 
The data available for the 
AccuTnI+3 assay itself could not be 
considered sufficient to determine 
its diagnostic accuracy. 
DG16(15) Both base-case analyses 
produced ICERs of less than 
£6,000 per QALY gained for the 
My5-FU assays.  
 
The My5-FU assay is only 
recommended for use in research 
for guiding dose adjustment in 
people having fluorouracil 
chemotherapy by continuous 
infusion. 
Model populated using data from the clinical 
effectiveness review, supplemented with expert 
opinion. Overall survival curves differed substantially 
between the identified studies, therefore two base-
case analyses were developed (see DG for more 
details). 
The duration, effect and cost of 2nd-line therapy are 
independent of 1st-line therapy. Some adverse effects 
were assumed to have no impact on quality of life and 
no end of life costs were applied. It was assumed that 
My5-FU assay effectiveness is similar to high-
performance liquid chromatography. 
Uncertainty whether the dose 
adjustment algorithms would be 
transferrable between the 
different cancers. 
The studies used did not provide 
sufficiently robust estimates to 
determine whether dose 
adjustment was clinically effective 
compared with body surface area 
dosing. 
No subgroup analyses or 
exploratory analyses for people 
with head and neck cancer were 
done due to lack of data. 
25 
 
DG Key results Conclusion Methods used 
Main assumptions 
Limitations 
DG17(16) Almost all (except two) of 
diagnostic strategies are 
dominated by clinical 
assessment when sensitivity 
level is set at 90%.  
The PROGENSA PCA3 assay and 
the PHI are not recommended for 
use in people having suspected 
prostate cancer. 
Model populated using data from the clinical 
effectiveness review.  
Number of cancers detected is always the same but 
number of biopsies to detect these cancers differ.  
Biopsy and its associated complications only have a 
short-term impact on quality of life. Biopsy is not linked 
with mortality. 
No primary studies collecting 
disutility values were identified. 
No meta-analyses were conducted 
due to the heterogeneity of 
clinical data and data from a single 
study was used in the analysis. 
Uncertainty in the sensitivity and 
specificity values used in the 
model. 
DG18(17) Base-case analyses showed that 
procalcitonin testing with 
standard clinical practice 
dominates standard clinical 
practice alone for all 
populations.   
All five procalcitonin tests show 
promise but there is currently 
insufficient evidence to 
recommend their routine adoption 
in the NHS. 
Model populated with data from the clinical 
effectiveness review and meta-analysis. 
All-cause mortality risks were assumed to be the same 
for adults as well as children.  No disutility for the 
hospital stay.  No costs associated with antibiotic-
related adverse events were included. 
Insufficient clinical evidence for 
children with sepsis in an intensive 
care setting. 
Unsure whether the reductions in 
resource use would be realised in 
the NHS. 
DG19(18) The VivaScope imaging systems 
were either cost-effective or 
when including other indications, 
the systems became the 
dominant strategy. 
 
The imaging systems show 
promise but there is currently 
insufficient clinical evidence to 
recommend their routine adoption 
in the NHS. 
Model populated with data from the clinical 
effectiveness review and supplemented by clinical 
opinion. 
Diagnostic accuracy of VivaScope 3000 was assumed to 
be equal to that of VivaScope 1500. Excision and biopsy 
was assumed to be the 'gold standard' for the diagnosis 
of melanoma. 
Lack of data specific to VivaScope 
3000 to determine its diagnostic 
accuracy. 
There was uncertainty around and 
limited data for the utility values. 
DG20(19) Base case 1: all interventions 
were dominated by blood 
culture. 
Base case 2: MALDI-TOF MS 
produced a positive net benefit 
compared with blood culture. 
The LightCycler SeptiFast Test 
MGRADE dominated 
MALDI-TOF MS and blood 
culture. 
Insufficient evidence to 
recommend the routine adoption 
of the three tests in the NHS. 
Model populated with data from the clinical 
effectiveness review and supplemented by clinical 
opinion. Base case 1: used data from the review & Base 
case 2: used expert opinion. 
30-day mortality rate was the only parameter to affect 
QALY gain/loss. Negative or failed rapid tests did not 
affect any of the 4 key outcomes. Blood culture was 
assumed to be 100% accurate and an imperfect 
reference standard. 
Insufficient evidence to establish 
either the diagnostic accuracy or 
the clinical utility of the other two 
tests against MALDI-TOF MS.  
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DG Key results Conclusion Methods used 
Main assumptions 
Limitations 
DG21(20) The base case results found that 
the MiniMed Paradigm Veo 
system and the Vibe and G4 
PLATINUM CGM system were 
not cost-effective when 
compared with capillary blood 
testing.  
 
MiniMed Paradigm Veo system is 
recommended as an option for 
managing blood glucose levels in 
people with type 1 diabetes under 
two conditions (see DG for further 
information). The Vibe and G4 
PLATINUM CGM system shows 
promise but insufficient evidence 
to support its routine adoption in 
the NHS. 
Model populated with data from the clinical 
effectiveness review and supplemented by clinical 
opinion. 
Non-integrated continuous glucose monitoring and 
continuous subcutaneous insulin therapy, were 
assumed to be clinically equivalent to that of the Vibe 
and G4 PLATINUM CGM system due to lack of data. 
Comparator - continuous glucose 
monitoring with multiple daily 
insulin injections were excluded 
because of the lack of clinical data.  
 
DG22(21) Second base-case model - testing 
strategies cheaper but less 
effective than standard care. 
First base-case model - testing 
strategies became more costly 
and less effective than no-testing 
strategy.  
The tests show promise but there 
is insufficient evidence to 
recommend their routine adoption 
across the NHS. 
Model populated with data from the clinical 
effectiveness review and supplemented by clinical 
opinion.  Two base-cases with different transition 
probabilities (1: non-constant hazard; and 2: constant 
hazard). 
Used alternative tests to provide clinical outcomes for 
the model. 
No direct clinical outcome data for 
the index tests. 
Insufficient evidence to link any of 
the index tests to alternative tests 
used in the model for the clinical 
outcomes. 
DG23(22) For women before 35 weeks 
gestation: the PlGF tests 
dominated standard clinical 
assessment. 
For women between 35 and 37 
weeks gestation: the PlGF tests 
were cost saving compared with 
standard clinical assessment. 
There was no difference in 
QALYs, therefore, ICERs were not 
calculated. 
Triage PlGF and the Elecsys 
immunoassay sFlt-1/PlGF ratio are 
recommended to help rule-out 
suspected pre-eclampsia in some 
women.  DELFIA Xpress PlGF 1-2-3 
test and BRAHMS sFlt-1 
Kryptor/BRAHMS PlGF plus 
Kryptor PE ratio are not 
recommended for routine 
adoption in the NHS. 
Linked evidence approach linking diagnostic test 
accuracy and prevalence of pre-eclampsia (obtained 
from literature) to maternal, fetal and neonatal 
outcomes.  
Two different outcomes for pre-eclampsia for the 
Triage PlGF test and the Elecsys immunoassay 
sFlt-1/PlGF ratio test were assumed to be the same. 
Utility scores for birth are assumed to last for 3 weeks. 
No head-to-head comparisons of 
index tests was available. 
The BRAHMS sFlt-1 
Kryptor/BRAHMS PlGF plus 
Kryptor PE ratio and the DELFIA 
Xpress 1-2-3 PlGF test were not 
included in the economic analysis 
because of insufficient data. 
Only short-term outcomes 
included, therefore QALYs are 
likely to be underestimated. 
DG24(23) ImmunoCAP ISAC and Microtest 
appeared to be cost saving 
compared with the standard 
clinical assessment. 
Currently insufficient evidence to 
recommend the routine adoption 
of the tests. 
A conceptual model was developed that showed the 
data and parameters that are needed. 
As no information, assumptions were needed on: 
proportion of people needing a particular test; accuracy 
of diagnostic pathways, treatment decision, probability 
of allergic reactions, probability of remission and 
probability of dying. 
Nine studies identified were all 
conference abstracts. 
No clinical evidence on Microtest 
as it was a new test. 
No studies identified that reported 
clinical outcomes. 
No reference standard. 
No de novo economic model was 
developed due to the lack of 
clinical effectiveness data. 
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DG Key results Conclusion Methods used 
Main assumptions 
Limitations 
DG25(24) NIPT strategies cost less and are 
less effective than current 
clinical practice. 
NIPT testing is recommended 
provided that the overall cost of 
testing is £24 or less. 
Model populated with data from the clinical 
effectiveness review and meta-analysis. 
Inconclusive NIPT result treated same as women who 
test positive in terms of routine antenatal anti-D 
prophylaxis.  No adverse health effects from using anti-
D immunoglobulin. 
Cost of test was uncertain and still 
under negotiation and cost did not 
include sample transport costs. 
 
 
DG26(25) In all models – XTAG GPP 
dominated conventional testing; 
whereas FilmArray GI Panel 
dominated conventional testing 
for the 3 hospital models and the 
two community models the ICER 
was not within the NICE cost-
effectiveness threshold. 
Currently insufficient evidence to 
recommend the routine adoption 
of these new tests in the NHS. 
 
Linked evidence approach linking diagnostic accuracy 
and prevalence data from the clinical effectiveness 
review to clinical end outcomes.  
Conventional testing was assumed to 100% accurate.  
Minimum number of bed days for both arms was 3 
days. 
Short time-frame – model did not 
take into account adverse events, 
readmissions or mortality. 
No economic analyses conducted 
for the Faecal Pathogens B assay 
due to lack of clinical data. 
Absence of reference standard. 
Lack of clinical outcome data for 
the new tests. 
DG27(26) Pairwise ICERs were compared 
with no testing (strategy 1) and 
only strategy 10 (universal 
genetic testing) had an ICER 
above £20,000/QALY gained.  
When all strategies were 
compared, microsatellite 
instability testing were either 
dominated or extendedly 
dominated by other strategies. 
To offer testing to all people with 
colorectal cancer, using  
microsatellite instability or 
immunohistochemistry. 
Model populated with data from the clinical and cost-
effectiveness reviews and 10 diagnostic strategies were 
compared. 
Sensitivity of microsatellite instability or 
immunohistochemistry testing did not depend on 
which mismatch repair gene is mutated.  Disutility only 
applied to people with stage IV colorectal cancer. 
Absence of direct comparative 
data. 
Microsatellite instability and 
immunohistochemistry were 
assumed to be clinically 
equivalent. 
DG28(27) Pairwise analyses found NBI & i-
scan dominated histopathology; 
FICE was cost saving and less 
effective than histopathology. 
Incremental analyses found 
histopathology was dominated 
by NBI and i-scan; and NBI was 
dominated by i-scan.  I-scan 
compared with FICE had an ICER 
of £10,466 per QALY gained. 
All three virtual chromoendoscopy 
tests are recommended to assess 
polyps of 5mm or less during 
colonoscopy, instead of 
histopathology. 
Model populated with data from the clinical 
effectiveness review and meta-analysis. 
People with polyps larger than 5mm were not included 
in the model. The disutility of bleeding was assumed to 
be the similar to a major gastrointestinal bleed. 
Comparator histopathology was assumed to be 100% 
accurate. 
No disutility values for adverse 
events during polypectomy were 
found. 
Cost of upgrading the equipment 
was not included in the model. 
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Key: BIS - Bispectral Index; CT – computed tomography; DG – Diagnostic guidance; EEG – Electroencephalography; EGFR-TK - epidermal growth factor receptor tyrosine 
kinase; ELISA - enzyme-linked immunosorbent assay; FeNO - Fractional exhaled nitric oxide; FICE - Flexible spectral imaging colour enhancement; GPP - Gastrointestinal 
Pathogen Panel; IBD - Inflammatory bowel disease; IBS - Irritable bowel syndrome; ICERs – incremental cost-effectiveness ratios; MRI – magnetic resonance imaging; NBI – 
narrow band imaging; NIPT - non-invasive prenatal testing; p.a. – per annum; PHI – Prostate Health Index; PIGF – placental growth factor; POCTs - point-of-care tests; 
QALYs – quality-adjusted life years; SeHCAT - tauroselcholic [selenium] acid test; TNF - tumour necrosis factor; 5-FU - 5-fluorouracil 
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Table 3: Critical appraisal of the economic evaluation studies using the CHEERS checklist (Husereau et al, 2013) 
CHEERS 
item \  
DG no. 
1 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
Title and abstract 
1  N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
2  N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Introduction 
3  Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Methods 
4  Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
5  Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
6  N N N N Y N Y N Y N N Y N N Y N N N Y Y N N N N Y Y Y 
7  Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
8  N N N Y N Y N Y Y Y N Y Y Y Y Y Y N Y Y Y N Y N Y Y Y 
9  P Y N N Y N Y N N N N Y N Y Y Y N Y Y Y N N N N Y Y Y 
10  Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
11a  N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
11b  P P Y Y Y Y Y N Y Y Y Y Y Y Y Y Y P Y Y Y Y Y Y Y Y Y 
12  N N N P P Y Y N Y Y Y Y Y Y Y Y Y P Y Y Y Y N Y Y Y Y 
13a  N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
13b  P P P Y P Y Y P Y Y Y Y P P Y P Y P Y Y Y P Y Y Y Y Y 
14  N N N Y N N Y N N N N Y N N N N N N N Y N N N Y N Y Y 
15  P Y Y Y P Y Y Y P Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
16  N N N N N N N N N N N N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
17  N N N N N N N N N N N N N N N N N N N N P N N N N N N 
Results 
18  N N P P P Y P P Y Y P Y P P Y P Y P Y Y Y Y P Y Y Y Y 
19 N Y Y Y N N P P Y P Y Y Y Y Y P Y N N Y Y Y N Y Y Y Y 
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20b  P N Y Y Y Y Y P Y Y Y Y Y Y Y Y Y Y P Y Y Y Y Y Y Y Y 
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Discussion 
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Other 
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Figure 1: Key steps involved in the DAR process [Source: edited from the DAP manual, 2011] 
 
 
Manufacturers provide evidence on the diagnostic technology
EAG report is shared with stakeholders for comment 
NICE commissions an External Assessment Group (EAG) to independently review 
the clinical and cost-effectiveness evidence
Topics selected for review are based on notifications and referred by the Medical 
Technologies Advisory Committee (MTAC)
MTAC team prepare a briefing note. NICE MTAC Committee decide whether 
technology is suitable for evaluation
NICE team prepares a scope (defines disease, patients, technology, care pathway 
and questions to be addressed)
Public consultation process is launched inviting stakeholders, health professionals, 
patients, carers and clinical experts to be part of the assessment process
Diagnostics Advisory Committee (DAC) considers the report and stakeholders 
feedback and provides draft recommendations
Diagnostic consultation document (DCD) with provisional recommendations is 
then open for comments by stakeholders and the public
A second DAC may be necessary to consider further information/analysis
Final outcome of the process is the publication of a Diagnostics Guidance (DG) 
report
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Figure 2. Findings and recommendations of 27 Diagnostic Guidances published by NICE by 30 May 2017 
 
CE: Recommend for 
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